News | Coronavirus (COVID-19) | March 03, 2020

FDA and CDC Take Action to Increase Access to Respirators to Protect Healthcare Workers From Coronavirus (COVID-19)

Agencies are expanding use of NIOSH-approved N95 face maskes for healthcare personnel

Can a N95 mask be worn instead of a surgical hospital mask to protect against Coronavirus? The answer according to the FDAand CDC is yes, and efforts are underway to make these masks more available to healthcare workers in the U.S.#COVID2019 #COVID19 #coronavirus #2019nCoV #wuhanvirus

March 3, 2020 — On March 2, in a joint effort, the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention took action to make more respirators, including certain N95s, available to healthcare personnel. Currently, the majority of respirators on the market are indicated for use in industrial settings. This action allows certain National Institute for Occupational Safety and Health (NIOSH) approved respirators not currently regulated by the FDA to be used in a health care setting by health care personnel during the coronavirus (COVID-19) outbreak, thereby maximizing the number of respirators available to meet the needs of the U.S. health care system.

“President Trump has made it clear that protecting the American people is his top priority, and that includes taking every necessary step to ensure America’s healthcare providers have the tools they need,” said HHS Secretary Alex Azar. “The FDA and CDC’s action to allow a wider range of respirators to be used in healthcare settings will help those on the front lines of this outbreak and their patients, which will keep all Americans safe. We will continue pursuing every possible avenue to secure the protective gear needed for responding to the COVID-19 outbreak.”

Respiratory protective devices are designed to achieve a very close facial fit and very efficient filtration of airborne particles. When properly fitted, respirators, such as N95s, can filter more airborne particles than face masks, which is important during an outbreak of a respiratory disease like COVID-19. The FDA regulates respirators intended for use in a health care setting, however, most respirators are used in construction and other industrial jobs only and are therefore not required to meet the FDA requirements for testing.

On March 2, the FDA granted the CDC’s request for an emergency use authorization (EUA) to allow health care personnel to use certain industrial respirators during the COVID-19 outbreak in health care settings. The FDA concluded that respirators approved by NIOSH, but not currently meeting the FDA’s requirements, may be effective in preventing health care personnel from airborne exposure, including COVID-19, which can cause serious or life-threatening disease, including severe respiratory illness. Given the increased demand and supply challenges on the availability of respirators, today’s EUA helps to provide alternatives that can enable more health care personnel to have access to this potentially lifesaving personal protective equipment. This action is the result of the close collaboration between the FDA and the CDC to prioritize access to needed medical products during this outbreak to support health care personnel.

“The FDA, alongside the CDC and other federal, state and local partners, have been aggressively addressing the COVID-19 outbreak,” said FDA Commissioner Stephen M. Hahn, M.D. “At the FDA, we’ve been working diligently to mitigate any potential shortages in the supply chain, including addressing increased demand and supply challenges associated with personal protective equipment. It is imperative that we assure health care personnel on the front lines of this outbreak have sufficient supplies of respiratory protective devices. Actions like today’s emergency use authorization are one of many tools the FDA can utilize during a public health emergency to respond to critical public health needs.”

Of note, the agencies are not currently aware of specific widespread shortages of personal protective equipment, but there are reports of increased ordering of these products and shortages have been observed in some U.S. health care institutions. The FDA and CDC are aware that as the COVID-19 outbreak continues to expand globally, the supply chain for these devices will continue to be substantially stressed as demand exceeds available supplies. Under the circumstances of this emergency, nationwide shortages are anticipated. The FDA and CDC are taking steps to address the observed and anticipated shortages by expanding the use of respirators that are NIOSH approved, but do not currently meet FDA regulatory requirements. This action today is part of an overall HHS strategy to help optimize the availability and use of respirators for health care personnel.

“The action taken today by CDC and the FDA will increase the availability of N95 respirators to healthcare professionals across the country and we will continue to work together with our agency partners to protect the health and safety of all Americans,” said CDC Director Robert R. Redfield, M.D. “It is important to remember the best way to prevent the spread of respiratory disease is by using everyday preventative actions. These include hand washing, using tissues to cover a cough, disinfecting frequently-touched surfaces and keeping distance from people who are coughing and sneezing. CDC does not recommend the use of masks by the general public.”

Additionally, while the EUA today can help increase the availability of certain NIOSH-approved respirators to health care personnel, this EUA does not apply to the public, who should not wear these respirators to protect against COVID-19. There is no added health benefit to the general American public to wear a respiratory protective device (such as an N95 respirator). The immediate health risk from COVID-19 is considered low. The CDC recommends everyday preventive actions, such as hand washing, to help prevent the spread of respiratory diseases.

The FDA will continue to update the public on our efforts to respond to this outbreak and efforts to find solutions to help mitigate any supply chain challenges that may arise, including continuing to assess the potential impacts of this outbreak on availability of medical devices and personal protective equipment. We are committed to working with stakeholders across the supply chain in close collaboration with public health and government partners to help enable access to critical medical products.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Should a surgical mask or N95 mask be used with coronavirus patients? #coronavirus #COVID19 #wuhanvirus #2019nCoV

 

N95 Mask vs. Surgical Mask

The main difference between surgical face masks and N95 respirators is that surgical masks are designed to protect the patients and environment from contamination from the person wearing it. The N95 respirator is designed to protect the person wearing it from particulates in the air, which include dust and droplets. The CDC said surgical masks do not provide the wearer with reliable level of protection from inhaling smaller airborne particles and is not considered respiratory protection.[1] This is mainly due to the surgical masks used by hospitals being loose fitting. The N95 is supposed to be tight fitting to prevent particles from getting into the mask. 

Although N95 respirators appeared to have a protective advantage over surgical masks in laboratory settings, a 2016 study meta-analysis showed that there were insufficient data to determine definitively whether N95 respirators are superior to surgical masks in protecting health care workers against transmissible acute respiratory infections in clinical settings.

For more information on M95 respirators from the CDC.

For more information on M95 masks from the FDA.

 

 

Related Coronavirus Content:

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

Emerging Technologies Proving Value in Chinese Coronavirus Fight

The Cardiac Implications of Novel Coronavirus

Radiologists Describe Coronavirus CT Imaging Features

Coronavirus Update from the FDA

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

Infervision in the Frontlines Against the Coronavirus

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Chest CT Findings of Patients Infected With Novel Coronavirus 2019-nCoV Pneumonia 

Find more related clinical content Coronavirus (COVID-19)

FDA Resource on the Novel coronavirus (COVID-19)

Mount Sinai Physicians the First in U.S. Analyzing Lung Disease in Coronavirus Patients from China

 

References:

1. Infographic - Understanding the Difference, Surgical Mask, N95 Respirator. CDC website. https://www.cdc.gov/niosh/npptl/pdfs/UnderstandDifferenceInfographic-508.pdf. Accessed Mar. 3, 2020. 

2. Jeffrey D. Smith, MSc, Colin C. MacDougall, MSc, Jennie Johnstone, et al. Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis. CMAJ. 2016 May 17; 188(8): 567–574. Published online 2016 Mar 7. doi: 10.1503/cmaj.150835

Related Content

Ziehm Imaging will showcase its leading portfolio of mobile C-arms and advanced pre- and intraoperative image-based decision support solutions on its virtual RSNA 2020 booth
News | Mobile C-Arms | November 20, 2020
November 20, 2020 — Ziehm Imaging will showcase its leading portfolio of...
Chest X-ray image of patient with lung injury due to vaping. Image courtesy of UC Regents #COVID19 #pandemic

Chest X-ray image of patient with lung injury due to vaping. Image courtesy of UC Regents

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — A UC Davis Health ped
1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well

1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well as elevated Lac. B, A patient with COVID-19 after recent PEA cardiac arrest with subtle FLAIR hyperintense white matter changes also shows elevated Cho/Cr and decreased NAA/Cr ratios. However, these derangements are less severe than in the patient in A. There is no clear elevation of Lac. C, A patient with COVID-19 without encephalopathy or recent severe hypoxia has normal Cho/Cr, with mildly decreased NAA/Cr and no lactate elevation. Cho, Choline; NAA, N-Acetyl-Aspartate; mI, Myo-Inositol; Lac, Lactate; Glx, Glutamate + Glutamine. Image courtesy of AJNR

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — One of the first spectroscopic imaging-based studies of neurological injury in...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
Videos | November 18, 2020
An example of a COVID-19 (SARS-CoV-2) pneumonia on chest computed tomography (CT) scan.